Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
NEW YORK - MVP Health Care and Renalytix plc (LSE:RENX) (OTCQB:RNLXY) announced Thursday a partnership to provide kidneyintelX.dkd testing to MVP’s 700,000 members in the northeastern United States.
The collaboration aims to mitigate the progression of chronic kidney disease in MVP’s type 2 diabetes patient population by implementing the FDA-approved risk assessment test across MVP’s physician network.
KidneyintelX.dkd, which assesses patient-specific risk for progressive decline in kidney function, will be available to MVP’s entire New York membership. The test is recommended for use by KDIGO, the international kidney disease clinical guidelines, and has Medicare reimbursement approval.
"At MVP Health Care, we are committed to delivering innovative, affordable solutions that improve access to care and support better health for our members," said Dr. Richard Dal Col, President of MVP Health Care, in a press release statement.
The partnership seeks to enable clinicians to better target resources, therapeutic options, and care plans for patients with chronic kidney disease, potentially slowing disease progression and improving outcomes, including those related to cardiovascular and metabolic comorbidities.
James McCullough, CEO of Renalytix, noted that in healthcare systems where kidneyintelX.dkd has been deployed, the company has observed measurable mitigation of CKD progression and improvements in blood pressure control and HbA1c levels in high-risk patients.
Renalytix describes its kidneyintelX.dkd as the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease.
MVP Health Care is a not-for-profit health insurer serving members primarily in the northeastern region of the United States.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.